Arcturus says ARCT-810 Phase 2 interim data in OTC deficiency show safety, biomarker improvement

Bitget2026/09/23 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arcturus reported interim Phase 2 data showing ARCT-810 was generally safe, with fasting ammonia maintained in-range and glutamine reduced.
LUNAR 2.0 delivery platform showed about 40-fold higher protein expression versus LUNAR 1.0 in non-human primates.
Separate primate study showed LUNAR 2.0 delivered 38-fold higher hOTC expression potency than ARCT-810’s key lipid ATX-95.
FDA feedback supports adding ARCT-2601, a LUNAR 2.0-based OTCD candidate, into the ongoing Phase 2 study near year-end for ages 12+.
ARCT-2601 is expected to enable lower or less frequent dosing versus ARCT-810, based on non-human primate data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609231601BIZWIRE_USPR_____20260923_BW761420) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcturus says ARCT-810 Phase 2 interim data in OTC deficiency show safety, biomarker improvement

You may also like

Crypto prices